GlassScriptPhysician profile
Philip J Muller
NPI 1891756128
$6,278.94
in general payments reported to CMS, 2019-2025
27 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $158 · 2021: $409 · 2022: $638 · 2023: $1,285 · 2024: $1,002 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960 · Education: $51.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.42 |
| Education | $51.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $890.61 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $752.11 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $691.41 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $563.46 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $469.76 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $452.95 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $439.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.91 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $231.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.61 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $199.14 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $197.29 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $139.12 | 2019-2025 | Ingrezza |
| Corium, LLC | $97.21 | 2023-2025 | Azstarys |
| Shire North American Group INC | $64.40 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $63.56 | 2024-2025 | Secuado, Xelstrym |
| Axsome Therapeutics, INC. | $54.11 | 2024-2025 | Auvelity |
| Bioxcel Therapeutics, INC. | $53.72 | 2023 | Igalmi |
| Almatica Pharma LLC | $45.56 | 2021 | |
| Indivior INC. | $45.02 | 2022-2023 | Perseris |
| Ironshore Pharmaceuticals INC. | $42.05 | 2021-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $35.17 | 2019 | |
| Collegium Pharmaceutical, INC. | $32.38 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $30.25 | 2020-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $28.83 | 2021-2022 | |
| Allergan, INC. | $13.98 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.